Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XGN |
---|---|---|
09:32 ET | 4008 | 2.87 |
09:33 ET | 100 | 2.81 |
09:35 ET | 350 | 2.8145 |
09:37 ET | 850 | 2.9 |
09:50 ET | 1200 | 2.85 |
09:55 ET | 664 | 2.81 |
10:08 ET | 174 | 2.7826 |
10:09 ET | 530 | 2.85 |
10:13 ET | 1900 | 2.85 |
10:18 ET | 300 | 2.8 |
10:22 ET | 350 | 2.8416 |
10:24 ET | 800 | 2.8844 |
10:26 ET | 251 | 2.77 |
10:27 ET | 300 | 2.835 |
10:29 ET | 376 | 2.8755 |
10:31 ET | 100 | 2.88 |
10:44 ET | 100 | 2.86 |
11:02 ET | 1000 | 2.8285 |
11:03 ET | 594 | 2.87 |
11:05 ET | 903 | 2.77 |
11:07 ET | 2205 | 2.91 |
11:12 ET | 2000 | 2.7832 |
11:14 ET | 100 | 2.93 |
11:20 ET | 1181 | 2.95 |
11:25 ET | 100 | 2.95 |
11:41 ET | 200 | 2.95 |
12:01 ET | 3556 | 3 |
12:03 ET | 2746 | 3.06 |
12:06 ET | 650 | 3.08 |
12:08 ET | 145 | 3.08 |
12:14 ET | 1958 | 3.01 |
12:15 ET | 5000 | 2.947 |
12:35 ET | 106 | 2.948757 |
12:46 ET | 100 | 3.05 |
12:48 ET | 100 | 2.995 |
01:04 ET | 230 | 3.025 |
01:11 ET | 100 | 3 |
01:22 ET | 100 | 3.025 |
01:29 ET | 100 | 3.01 |
01:40 ET | 200 | 3 |
01:44 ET | 100 | 3.025 |
01:51 ET | 200 | 3 |
02:00 ET | 300 | 3 |
02:14 ET | 100 | 2.95 |
03:35 ET | 100 | 2.98 |
03:53 ET | 200 | 2.99 |
04:00 ET | 1357 | 2.98 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Exagen Inc | 50.4M | -3.2x | --- |
New York Health Care Inc | 38.9M | 0.0x | --- |
Cryo-Cell International Inc | 70.4M | -7.8x | --- |
Prophase Labs Inc | 17.5M | -0.5x | --- |
Global Cord Blood Corp | 167.4M | 2.3x | +20.97% |
Psychemedics Corp | 13.9M | -3.0x | --- |
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $50.4M |
---|---|
Revenue (TTM) | $55.8M |
Shares Outstanding | 17.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.35 |
EPS | $-0.94 |
Book Value | $1.33 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 0.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -27.62% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.